# Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia

> **NCT00492336** · PHASE4 · COMPLETED · sponsor: **University of Maryland, Baltimore** · enrollment: 84 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** rasagiline (Pharmacodynamics)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00492336
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2019-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00492336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00492336, "Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00492336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*